The Food and Drug Administration (FDA) has a labyrinthine approval process for new drugs. This is good news for consumers, bad news for drug companies and an opportunity for short-term traders. The approval process creates intense price volatility among the publicly traded companies that are involved, particularly those early stage companies with little revenue.

There are several companies with approvals pending before the FDA that a trader can build either long or short positions around to take advantage of this volatility.

Early Stage Biotech
In February 2008, the FDA accepted a review request by Cypress Bioscience (Nasdaq:CYPB) and Forest Laboratories (NYSE:FRX) for a new drug application for Milnacipran, a drug for use in treating fibromyalgia syndrome. Milnacipran was approved for use in Austria but Cypress is attempting to bring it to North America. An approval or rejection decision is expected at the end of October 2008. If approved the drug can legally be marketed and sold. (To begin with the analysis basics, read Measuring The Medicine Makers.)

Cypress Bioscience is an early-stage biotechnology company that had only $15 million in revenue in the first six months of 2008. Almost all of the revenue was payments from Forest Labs in connection with Milnacipran. A negative decision from the FDA might be devastating to the company, although the company did have $153.4 million in cash, cash equivalents and short-term investments as a cushion at the end of the June quarter. Either way, a binary outcome is probable.

Forest Labs is a more diversified company with revenue in its latest fiscal year of $3.8 billion so the upcoming FDA decision on Milnacipran will have less impact on this company. Forest Lab's two main drugs are Lexapro, used to treat depression, which represented 66% of sales, and Namenda, used to treat Alzheimer's disease, which was 24% of sales in fiscal 2008.

Ligand Pharmaceuticals (Nasdaq:LGND) is another early-stage drug company with a new drug application pending before the FDA. Ligand technology was used in the development of Fablyn, which can treat osteoporosis, and was developed in collaboration with Pfizer (NYSE:PFE). An FDA panel gave the chances for approval a boost in early September 2008, when it said the drug might prove more beneficial to patients given the risks. Ligand had only $9.7 million in revenues the first six months of 2008. The company is not solely dependent on Fablyn, as it has collaborations with other large drug companies including Wyeth (NYSE:WYE) and GlaxoSmithKline plc (NYSE:GSK). A decision is expected sometime before the end of 2008 and if approved Ligand will receive royalty payments and cash.

Discovery Laboratories (Nasdaq:DSCO) is seeking approval for a drug called Surfaxin for the prevention of respiratory distress syndrome (RDS) in premature infants. The company only had about $4.5 million in revenue in the first six months of 2008. The FDA issued an approvable letter in May 2008, and Discovery Labs is expected to respond to that letter shortly. If the response is designated a "class 1" resubmission, then a decision is expected from the FDA before the end of the year.

Bottom Line
Volatility is the lifeblood of a trader, and the binary outcome of the FDA new drug application process provides plenty of it.

For more on trading the biotech industry and the drug approval process, read The Ups And Downs Of Biotechnology.

Related Articles
  1. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  2. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  3. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  4. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  5. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  6. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  7. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  8. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  9. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  10. Stock Analysis

    GoPro's Stock: Can it Fall Much Further? (GPRO)

    As a company that primarily sells discretionary products, GoPro and its potential falls right in line with consumer trends. Is that good or bad?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center